|
PDR resistant vs no PDR/susceptible
|
1.78
|
(0.89–3.54)
|
0.101
| |
1.42
|
(0.62–3.24)
|
0.400
| |
|
Sex (male vs female)
|
1.06
|
(0.71–1.60)
|
0.770
| |
1.45
|
(0.91–2.31)
|
0.117
| |
|
Age (per additional year)
|
0.89
|
(0.84–0.93)
|
0.000
| |
0.88
|
(0.82–0.95)
|
0.0005
| |
|
Origin (ref Europe)
| | | |
0.029
| | | |
0.720
|
|
Africa
|
0.40
|
(0.20–0.78)
|
0.008
| |
1.14
|
(0.49–2.62)
|
0.759
| |
|
Asia
|
0.73
|
(0.45–1.18)
|
0.197
| |
1.02
|
(0.464–2.25)
|
0.960
| |
|
Other/unknown
|
1.10
|
(0.58–2.09)
|
0.764
| |
0.65
|
(0.28–1.50)
|
0.313
| |
|
Previous AIDS diagnosis (yes vs no)
|
1.18
|
(0.73–1.91)
|
0.495
| |
1.00
|
(0.56–1.76)
|
0.986
| |
|
Pretreatment CD4 count (per 100 cells/mm3)
|
1.01
|
(0.98–1.04)
|
0.510
| |
0.96
|
(0.92–1.00)
|
0.048
| |
|
Pretreatment viral load (per 1 log10 copies/mL increase)
|
1.16
|
(0.90–1.50)
|
0.254
| |
0.99
|
(0.76–1.28)
|
0.987
| |
|
Subtype (non B vs B)
|
0.85
|
(0.48–1.50)
|
0.569
| |
0.70
|
(0.34–1.45)
|
0.335
| |
|
Year of treatment start (ref: 2007–2008)
| | | |
0.018
| | | |
0.818
|
|
1998–1999
|
3.14
|
(1.22–8.07)
|
0.018
| |
1.11
|
(0.25–4.95)
|
0.891
| |
|
2000–2002
|
2.01
|
(0.71–5.70)
|
0.190
| |
1.89
|
(0.48–7.40)
|
0.361
| |
|
2003–2004
|
1.97
|
(0.75–5.21)
|
0.170
| |
1.29
|
(0.34–4.96)
|
0.710
| |
|
2005–2006
|
1.36
|
(0.52–3.60)
|
0.532
| |
1.27
|
(0.34–4.79)
|
0.7230
| |
|
Antiretroviral drug combination (ref: NNRTI plus ≥ 2NRTIs)
| | | |
0.0002
| | | |
0.007
|
|
Unboosted PI plus ≥ 2NRTIs
|
19.5
|
(2.68; 1.73)
|
<0.001
| |
3.65
|
(1.65; 8.05)
|
0.001
| |
|
Boosted PI plus ≥ 2NRTIs
|
1.26
|
(0.56; 2.83)
|
0.572
| |
1.79
|
(0.76; 4.57)
|
0.222
| |
|
Other
|
1.73
|
(0.62; 4.85)
|
0.300
| |
2.65
|
(0.90; 7.81)
|
0.077
| |
